Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2922 in Recurrent/Metastatic Head and Neck Cancer
NCT07601204Phase 2Not yet recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Jun 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2922 in head and neck cancer (HNC), sponsored by Chia Tai Tianqing. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tqb2922
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07601204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601204.